Proteomics

Dataset Information

0

Glioma proteome organization under oncolytic adenoviral infection

ABSTRACT: Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant glioma. Oncolytic adenoviruses are being modified to exploit the aberrant expression of proteins in tumor cells to enhance tumor tropism and glioma-selective replication. E1A mutant adenovirus Delta-24-RGD has shown favorable toxicity profile and remarkable efficacy in a first-in-human phase I clinical trial. However, the comprehensive modulation of glioma metabolism in response to Delta-24-RGD infection is poorly understood. Integrating mass spectrometry based-quantitative proteomics, physical and functional interaction data, and biochemical approaches, we conducted a cell-wide study of cytosolic, nuclear, and secreted glioma proteomes throughout the early time course of Delta-24-RGD infection.

INSTRUMENT(S): TripleTOF 5600

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain, Astrocyte

DISEASE(S): Glioblastoma

SUBMITTER: Enrique Santamaría  

LAB HEAD: enrique santamaria

PROVIDER: PXD008022 | Pride | 2018-10-22

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
092todaslasfraccionesv2.group Other
092todaslasfraccionesv2__FDR.xlsx Xlsx
100mMB-092iTRAQ21092016-1.wiff Wiff
100mMB-092iTRAQ21092016-1.wiff.scan Wiff
125mMB-092iTRAQ21092016-2.wiff Wiff
Items per page:
1 - 5 of 16
altmetric image

Publications

Spatial and temporal proteome dynamics of glioma cells during oncolytic adenovirus Delta-24-RGD infection.

González-Morales Andrea A   Zabaleta Aintzane A   Guruceaga Elizabeth E   Alonso Marta M MM   García-Moure Marc M   Fernández-Irigoyen Joaquín J   Santamaría Enrique E  

Oncotarget 20180724 57

Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant glioma. Oncolytic adenoviruses are being modified to exploit the aberrant expression of proteins in tumor cells to increase the antiglioma efficacy. E1A mutant adenovirus Delta-24-RGD (DNX-2401) has shown a favorable toxicity profile and remarkable efficacy in a first-in-human phase I clinical trial. However, the comprehensive modulation of glioma metabolism in response to Delta-24-RGD infection is poorly understoo  ...[more]

Similar Datasets

Proteomics Modulation of glioma cell proteome by Delta-24-RGD adenovirus (48hpi)
2018-12-11 | PXD010256 | Pride
Proteomics Modulation of glioma cell proteome by Delta-24-RGD adenovirus (24hpi)
2018-12-11 | PXD011580 | Pride
Proteomics nuclear proteomics of glioma cells infected with an oncolytic adenovirus
2018-10-22 | PXD008023 | Pride
Transcriptomics Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells
2011-04-16 | E-GEOD-28618 | biostudies-arrayexpress
Transcriptomics The target genes of EGFR activity in glioma cells
2011-11-05 | E-GEOD-33442 | biostudies-arrayexpress
Transcriptomics IGFBP2 driven glioma progression is prevented by blocking a clinically significant network of integrin, ILK, and NK-kB
2012-02-02 | E-GEOD-35467 | biostudies-arrayexpress
Other Analyses of immune infiltrate in DIPG murine models after treatment with new oncolytic virus Delta-24-ACT
2022-05-11 | GSE197374 | GEO
Transcriptomics miRNA analysis of HBMVECs exposed or unexposed to U87 glioma cells
2010-06-25 | E-GEOD-13091 | biostudies-arrayexpress
Transcriptomics The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models [RNA-seqII]
2024-05-09 | GSE255971 | GEO
Transcriptomics The oncolytic adenovirus Delta-24-RGD in combination with ONC201 displays a potent antitumor effect in pediatric high-grade glioma models [RNA-seqI]
2024-05-09 | GSE243223 | GEO